z-logo
open-access-imgOpen Access
Structural revision of sesbagrandiflorains A and B, and synthesis and biological evaluation of 6-methoxy-2-arylbenzofuran derivatives
Author(s) -
Noviany Noviany,
Arash Samadi,
Evan L. Carpenter,
Mostafa E. Abugrain,
Sutopo Hadi,
Neny Purwitasari,
Gitali Indra,
Arup K. Indra,
Taifo Mahmud
Publication year - 2020
Publication title -
natural medicines/journal of natural medicines
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.512
H-Index - 46
eISSN - 1861-0293
pISSN - 1340-3443
DOI - 10.1007/s11418-020-01445-2
Subject(s) - benzofuran , chemistry , natural product , stereochemistry , cytotoxicity , cancer cell lines , chemical structure , organic chemistry , in vitro , cancer cell , biology , cancer , biochemistry , genetics
Sesbagrandiflorains A (1) and B (2), isolated from the stem bark of the Indonesian fabaceous plant Sesbania grandiflora, were reported to be 6-methoxy-2-(2´,3´-dihydroxy-5´-methoxyphenyl)-1-benzofuran-3-carbaldehyde and 6-hydroxy-2-(2´,3´-dihydroxy-5´-methoxyphenyl)-1-benzofuran-3-carbaldehyde, respectively. However, based on reevaluation of their 1D and 2D NMR data, the chemical structures of 1 and 2 have been revised to 4-hydroxy-2-(4´-hydroxy-2´-methoxyphenyl)-6-methoxybenzofuran-3-carbaldehyde and 4-hydroxy-2-(4´-hydroxy-2´-hydroxyphenyl)-6-methoxybenzofuran-3-carbaldehyde, respectively. In addition, seven new derivatives of 1 have been synthesized from the natural product in good yields (65 - 93%). The chemical structures of the synthetic compounds-one diester (6), four ethers (7-10), one secondary amine (11), and one oxime (12)-were confirmed by MS and NMR analysis. Compound 6 exhibited moderate antibacterial activity against the plant pathogen Rhodococcus fascians with a MIC of 0.1 mg/mL. Compounds 8 and 12 demonstrated respectable cytotoxicity against A375 melanoma cancer cells line with the relative IC 50 values of 22.8 and 32.7 μM, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here